On October 24, 2018, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act was signed into law. This legislation provides FDA and DEA, as well as several other agencies, with significant new authority to combat the opioid crisis. Join our expert FDA and private practice speakers to understand the tools the legislation provides to FDA and DEA, other efforts FDA is making to combat the opioid crisis, real-world impacts of the legislation, and whether more federal action is necessary to alleviate the high rates of opioid overdoses and deaths in the US.
- +$100 for nonmembers
Internet Explorer and Microsoft Edge are not supported by the checkout process.
John Gilbert, Director, Hyman, Phelps & McNamara, PC
Chad Landmon, Partner, Axinn, Veltrop & Harkrider LLP
J. Patrick Raulerson, Senior Regulatory Counsel, Office of Regulatory Policy, Center for Drug Evaluation and Research, FDA
Moderated by Jeffrey Francer, Senior Vice President & General Counsel, Association for Accessible Medicines
Virtual Learning FAQ
On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.
On-demand content can be played back on most devices.
If you have concerns, please click the Test Your System link to determine your device’s compatibility, as well as system requirements.
CLE credit is not currently available for pre-recorded sessions.